Key Drivers
- Gross margin strength
- Operating cost drag
- Leverage pressure
AIAI Summary
AXSM has shifted from a speculative biotech to a commercial-stage growth story, with the AUVELITY Alzheimer's-agitation approval expanding its addressable market, but the stock now hinges on whether fast revenue can finally outpace high SG&A and negative free cash flow to create real operating leverage.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Gross margin strength
- •Operating cost drag
- •Leverage pressure
AXSM's very strong gross margins and solid cash position are being offset by heavy operating खर्च, negative free cash flow, rising leverage, and a still-rich valuation, leaving profitability risk elevated.
Price Behavior
Key Price Behavior Insights:
- •Higher highs
- •Breakout hold
- •Support test
AXSM has turned from a mid-period dip into a constructive uptrend over the last month, with higher highs/lows, a successful breakout above $206, and key near-term support at $223–$224 that must hold to keep momentum intact.
Pullback from the $235.32 high signals profit-taking and softer short-term momentum
Sentiment & News
Key News Insights:
- •FDA approval
- •Revenue growth
- •Pipeline expansion
Axsome delivered a major catalyst with FDA approval of AUVELITY for Alzheimer's agitation, but the outlook remains mixed as strong 57% Q1 revenue growth and pipeline expansion were offset by a wider loss and below-consensus EPS.
This is a positive catalyst for the instrument, but sustained upside will likely depend on successful AUVELITY launch execution and improving profitability
Similar Companies in Healthcare
Other companies in the same sector with AI ratings